Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of “Hold” from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given an average rating of “Hold” by the twenty-nine brokerages that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $43.50.

A number of equities research analysts have recently commented on SRPT shares. Morgan Stanley raised their target price on Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 29th. Leerink Partners restated a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, July 21st. HC Wainwright restated a “sell” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Oppenheimer upgraded Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $30.00 to $37.00 in a research report on Tuesday, July 29th.

Sarepta Therapeutics Price Performance

Shares of SRPT opened at $20.58 on Thursday. The business’s 50-day moving average is $18.65 and its two-hundred day moving average is $52.02. The company has a market capitalization of $2.01 billion, a P/E ratio of -23.65 and a beta of 0.46. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $144.22.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million for the quarter, compared to analysts’ expectations of $530.66 million. During the same period last year, the firm earned $0.07 EPS. The company’s quarterly revenue was up 68.4% on a year-over-year basis. Research analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Capital International Investors lifted its stake in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after buying an additional 2,437,855 shares in the last quarter. Federated Hermes Inc. lifted its stake in Sarepta Therapeutics by 347.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock valued at $22,370,000 after buying an additional 1,016,069 shares in the last quarter. Norges Bank purchased a new position in Sarepta Therapeutics in the 2nd quarter valued at about $15,619,000. Y Intercept Hong Kong Ltd lifted its stake in Sarepta Therapeutics by 1,736.5% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after buying an additional 822,799 shares in the last quarter. Finally, Aberdeen Group plc lifted its stake in Sarepta Therapeutics by 91.1% in the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after buying an additional 592,125 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.